

**AWARD NUMBER:**

W81XWH-14-2-0132

**TITLE: Restoration of Bladder and Bowel Function Using Electrical Stimulation and Block after Spinal Cord Injury**

**PRINCIPAL INVESTIGATOR:** Graham Creasey, MD, FRCSEd

**RECIPIENT:** VA Palo Alto Health Care System/PAVIR, Palo Alto, CA

**REPORT DATE:**

October 2021

**TYPE OF REPORT:**

Annual

**PREPARED FOR:** U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

**DISTRIBUTION STATEMENT:** Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

*Form Approved*  
**OMB No. 0704-0188**

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> October 2021			<b>2. REPORT TYPE</b> Annual		<b>3. DATES COVERED</b> 29Sep2020 - 28Sep2021	
<b>4. TITLE AND SUBTITLE</b> Restoration of Bladder and Bowel Function Using Electrical Stimulation and Block after Spinal Cord Injury					<b>5a. CONTRACT NUMBER</b> W81XWH-14-2-0132	
					<b>5b. GRANT NUMBER</b>	
					<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b> Graham Creasey, MD, FRCSEd  Email: <a href="mailto:gcreasey@stanford.edu">gcreasey@stanford.edu</a>					<b>5d. PROJECT NUMBER</b>	
					<b>5e. TASK NUMBER</b>	
					<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> VA Palo Alto Health Care System/PAVIR 3801 Miranda Ave Palo Alto, CA 94304					<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012					<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
					<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited						
<b>13. SUPPLEMENTARY NOTES</b>						
<b>14. ABSTRACT</b>  The purpose of the project is to evaluate the restoration of bladder function using electrical stimulation and block after spinal cord injury in human subjects. Regulatory compliance has been maintained with the Institutional Review Boards and the Human Research Protection Office and Investigational Device Exemption has been maintained with the Food and Drug Administration. Nine subjects have been enrolled and undergone urodynamic evaluation, six of these have undergone neuromodulation by electrical stimulation via skin surface electrodes. and four responded to this neuromodulation. Two did not wish to proceed with surgical implantation of a bladder stimulator, one is considering implantation and one has undergone implantation. In this subject the implant has been successful in restoring micturition without catheterization and continence without medication or rhizotomy for the first time in 41 years. Three clinical sites are now part of the trial; recruitment is continuing and has identified several more suitable subjects who will be evaluated as the pandemic allows.						
<b>15. SUBJECT TERMS</b> Spinal Cord Injuries, Neurogenic Bladder, Electric Stimulation						
<b>16. SECURITY CLASSIFICATION OF:</b>				<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>	<b>19b. TELEPHONE NUMBER</b> (include area code)			
U	U	U	UU	10		

## TABLE OF CONTENTS

	<u>Page No.</u>
1. Introduction	3
2. Keywords	3
3. Accomplishments	3
4. Impact	5
5. Changes/Problems	6
6. Products	6
7. Participants & Other Collaborating Organizations	7
8. Special Reporting Requirements	8
9. Appendices	8

## 1. INTRODUCTION:

This is a Phase 1 clinical trial of an implanted electrical stimulator to improve both continence and voiding in human subjects with chronic spinal cord injury. It will use the existing FDA-approved Vocare stimulator and electrodes manufactured by Finetech Medical Ltd in England, implanting electrodes on the sacral nerves as usual but without performing posterior sacral rhizotomy. Conventional low frequency stimulation will be applied to the sacral nerves at a low amplitude to activate large afferent axons with the aim of inhibiting bladder contraction by neuromodulation, and bladder capacity and continence will be measured. Higher frequency stimulation will be applied at low amplitude and tested for its effectiveness in blocking sphincter contraction for the purpose of improving micturition.

## 2. KEYWORDS:

Spinal Cord Injuries, Neurogenic Bladder, Electric Stimulation

## 3. ACCOMPLISHMENTS:

### What were the major goals of the project?

1. Maintain regulatory compliance
2. Coordinate study staff for clinical trial
3. Participant recruitment, screening & surgery
4. Evaluation of continence
5. Evaluation of voiding
6. Data analysis and publication

## What was accomplished under these goals?

- 1) Major activities
  - Regulatory compliance maintained
  - Study staff for clinical trial maintained
  - Participant recruitment and screening continued
  - First non-veteran subject implanted and undergoing follow-up
- 2) Specific Objectives
  - To improve continence by electrical stimulation in human subjects with SCI
  - To improve voiding by electrical stimulation in human subjects with SCI
- 3) Significant results
  - Regulatory compliance maintained
    - a. FDA approval maintained
    - b. IRB approval maintained for Stanford University IRB, Santa Clara Valley Medical Center IRB and MetroHealth Medical Center (Cleveland) IRB
    - c. IRB approval awaited at University of New Mexico Hospital
    - d. HRPO approval maintained for VA Palo Alto, Santa Clara Valley Medical Center and MetroHealth Medical Center
    - e. Information on clinicaltrials.gov has been updated
- 4) Coordinate study staff for clinical trial
  - a. Staff training maintained at VA Palo Alto and Santa Clara Valley Medical Center, San Jose
  - b. Staff training at MetroHealth Medical Center, Cleveland, OH is in process
- 5) Participant recruitment, screening and surgery
  - a. First non-veteran subject has been successfully implanted at Santa Clara Valley Medical Center and has undergone programming of the device and urodynamic evaluation and two years follow-up.
  - b. Other veteran and non-veteran subjects being recruited within limits of pandemic
- 6) Evaluation of continence
  - a. The implant has been able to produce continence without anticholinergic medication or rhizotomy in non-veteran subject for the first time in 41 years.
- 7) Evaluation of micturition
  - a. The implant has been able to produce micturition without catheterization or rhizotomy in non-veteran subject for the first time in 41 years
  - b. External controller has been modified to test sphincter block for improving micturition
  - c. FDA Amendment approved for modification of external controller
- 8) Data analysis and publication
  - a. Data collection and analysis for the non-veteran subject with implant
  - b. Publication in Operative Neurosurgery
  - c. Presentation at International Neuro Urology Society
- 9) Other achievements
  - a. Funding of routine costs of clinical trial at Santa Clara Valley Medical Center under CMS National Coverage Determination 310.1 has been confirmed
  - b. A request for a clinical site at the University of New Mexico has been approved by DOD
  - c. A request for extension without funding for the next 12 months has been approved by DOD

### **What opportunities for training and professional development has the project provided?**

The Biomedical Engineer has received training from the biomedical engineering collaborators in the VA Functional Electrical Stimulation Center in Cleveland Ohio, and the Neurosurgeon and Urologist in Santa Clara Valley Medical Center have received training allowing them to carry out implants in non-veterans.

### **How were the results disseminated to communities of interest?**

A journal article and video was published by the journal Operative Neurosurgery in January 2020  
A presentation was given to the International Neuro Urology Society conference in Istanbul, Turkey in January 2020.

### **What do you plan to do during the next reporting period to accomplish the goals?**

1. Maintain existing IRB, HRPO and FDA approvals
2. Continue recruitment, screening, enrollment and evaluation of subjects at all clinical sites
3. Obtain IRB approval at the University of New Mexico
4. Confirm funding of routine costs of clinical trial at MetroHealth Medical Center, Cleveland, and University of New Mexico, Albuquerque, under CMS National Coverage Determination 310.1
5. Implantation of additional stimulators
6. Evaluation of bladder capacity and continence with implanted stimulator
7. Evaluate micturition with implanted stimulator using higher frequencies
8. Presentation at International Neuro Urology Society in Innsbruck, Austria, January 2022

## **4. IMPACT:**

### **What was the impact on the development of the principal discipline(s) of the project?**

The use of electrical stimulation to restore both bladder continence and emptying without destructive surgery has generated considerable interest in the discipline of spinal cord injury particularly in Britain, France, Australia and New Zealand.

### **What was the impact on other disciplines?**

Collaboration with biomedical engineers, particularly at the VA Functional Electrical Stimulation Center in Cleveland, Ohio, is defining new electrical stimulation parameters and protocols for management of the neurogenic bladder.

### **What was the impact on technology transfer?**

The approval by the Food and Drug Administration of Investigational Device Exemption for evaluation of both continence and voiding in this project will facilitate progress of the project towards technology transfer of the implantable electrical stimulator.

### **What was the impact on society beyond science and technology?**

Nothing to report yet.

## 5. CHANGES/PROBLEMS:

### Changes in approach and reasons for change

FDA approved expansion to a total of four sites in order to increase recruitment of non-veterans who more closely resemble current active-duty service members than the population of veterans initially targeted, who tend to be ageing and less interested in new techniques. We have set up three sites with IRB and HRPO approval and we plan to open a fourth site when approved by the IRB of the University of New Mexico.

*Describe problems or delays encountered during the reporting period and actions or plans to resolve them.*

Identification of suitable veteran subjects was initially slow and therefore we obtained FDA approval to expand to non-veterans and to open up to three additional sites. At one of these, the Santa Clara Valley Medical Center, the first non-veteran subject was implanted in June 2019 and is successfully using the implant to produce micturition without catheterization and continence without medication. At another of these, the MetroHealth Medical Center in Cleveland, IRB approval has been obtained and they plan to evaluate subjects as the pandemic allows. We plan to open the third additional site at the University of New Mexico when IRB approval is obtained there.

### Changes that had a significant impact on expenditures

In response to the delays caused by the pandemic we have re-budgeted existing research funds to follow up existing subjects and recruit additional subjects, and have confirmed with the Centers for Medicare and Medicaid Services that the routine clinical costs of the trial can be charged to Medicare under National Coverage Determination 310.1. This has allowed expansion of the trial to non-veteran hospitals at no extra cost to DOD.

### Significant changes in use or care of human subjects

Nothing to report

### Significant changes in use or care of vertebrate animals.

Not applicable

### Significant changes in use of biohazards and/or select agents

Not applicable

## 6. PRODUCTS:

### • Publications, conference papers, and presentations

Presentation to the International Neuro Urology Society Annual Conference January 2020, Istanbul, Turkey.  
Publication in Operative Neurosurgery 2020: Implantation of Sacral Nerve Stimulator Without Rhizotomy for Neurogenic Bladder in Patient With Spinal Cord Injury: 2-Dimensional Operative Video. Ehsanian R,

### Other publications, conference papers, and presentations.

Presentation accepted for the 2022 Conference of the International Neuro Urology Society in Innsbruck, Austria, January 2022.

- **Website(s) or other Internet site(s)**

Clinicaltrials.gov NCT02978638

- **Technologies or techniques**

Technique being developed for application of high frequency alternating current block.

- **Inventions, patent applications, and/or licenses**

Nothing to report

## 7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

### What individuals have worked on the project?

*Name: Graham Creasey  
Project Role: Project Director  
Nearest person month worked: 3.6  
Contribution to Project: Dr. Creasey has worked on training and coordination of other personnel and on confirming and maintaining regulatory compliance and correspondence with the VA, IRB and DOD and FDA. He has met with potential subjects, provided information to allow them to give informed consent, and carried out screening urodynamics. He has also visited the new sites to select collaborators and educate them about the project.*

*Name: Dennis Bourbeau (Case Western)  
Project Role: site PI  
Effort: 1.5mos CY (12.5%)  
Contribution to Project: subject recruitment, equipment maintenance, running experiments, data collection and analysis*

*Name: Kimberly Schach (Case Western)  
Project Role: site Study Coordinator  
Effort: 2.4mos CY (20%)  
Contributions: study coordination, subject recruitment*

**Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

No

**What other organizations were involved as partners?**

As planned in the grant application, collaboration has been established with the Functional Electrical Stimulation Center at the VA Medical Center in Cleveland Ohio, which is affiliated with the Bioengineering Department of Case Western Reserve University. This Center developed the technique of high frequency alternating current block in animals and has also studied the use of electrical stimulation for improvement of bladder capacity and continence after spinal cord injury. The biomedical engineering expertise available from the collaborators at the Functional Electrical Stimulation Center will be crucial in translating their basic research into clinical application in this project.

Clinicians at the Santa Clara Valley Medical Center in San Jose and the MetroHealth Medical Center in Cleveland have collaborated in obtaining IRB approval at these sites and recruiting and evaluating subjects. Clinicians at the University of New Mexico Hospital in Albuquerque are awaiting IRB approval.

**8. SPECIAL REPORTING REQUIREMENTS**

**COLLABORATIVE AWARDS:**

**QUAD CHARTS:** See attached

**9. APPENDICES:**

# Restoration of Bladder and Bowel Function using Electrical Stimulation and Block after Spinal Cord Injury W81XWH-14-2-0132



**PI:** Graham Creasey, MD

**Org:** Palo Alto Veterans Institute for Research

**Award Amount:** \$998,463

## Study/Product Aim(s)

- To improve continence by electrical stimulation in human subjects with SCI
- To improve voiding by electrical stimulation in human subjects with SCI

### Approach


The purpose of this study is to improve both continence and voiding of urine by electrical stimulation of nerves in patients with spinal cord injury. Electrical stimulation of the sacral nerves or roots has been used before to produce bladder contraction and improve voiding, but it has usually been combined with cutting of sacral sensory nerves to reduce reflex contraction of the bladder and sphincter. However, cutting the nerves has many undesirable side effects. A new protocol of electrical stimulation of nerves using a surgically implanted system without cutting nerves will now be tested for its ability to:

- Inhibit reflex contraction of the bladder and improve continence
- Block reflex contraction of the sphincter and improve voiding

## Timeline and Cost

Activities	FY	15	16	17	18	19	20	21
Obtain & maintain regulatory approvals		█						
Stage 1: Recruitment, Surgery, Evaluation			█					
Stage 2: Recruitment, Surgery, Evaluation					█			
Expansion of trial to non-veteran sites & identification of subjects						█		
<b>Estimated Budget (\$K)</b>		<b>\$126</b>	<b>\$333</b>	<b>\$245</b>	<b>\$121</b>	<b>\$171</b>	<b>\$</b>	<b>\$</b>

Updated: (10/27/2021)



Animal research studies have shown that stimulating sensory nerves can inhibit bladder contraction and high frequency stimulation of motor nerves can block action potential propagation and prevent unwanted external urethral sphincter contraction in order to produce bladder emptying. The effect of stimulation is easily reversible.

### Goals/Milestones

**FY15 Goal** – Initial Participant Recruitment, Screening & Evaluation

- Recruitment and screening of first participants
- Obtain FDA approval for Stage 1

**FY16 Goals** – Further Participant Recruitment, Surgery and Evaluation

- Continue with Recruitment and screening
- Evaluate patients in Urodynamic laboratory

**FY17 Goal** – Participant Evaluation

- Expand recruitment to non-veterans
- Evaluate continence and voiding in urodynamic laboratory

**FY18 Goal** – Further Participant Recruitment, Surgery and Evaluation

- Obtain FDA approval for non-veteran clinical trial sites

**FY19 Goal:** Expansion of trial to non-veteran sites

- Implant non-veteran

**FY20 Goal:** Implant further non-veteran subjects

- Evaluation and follow-up
- Additional site and recruitment

**FY21 Goal:** Enroll and implant further subjects when pandemic controlled

- Identified 173 potential non-veteran subjects
- Open fourth site for non-veteran subjects

**Budget Expenditure to Date**

Projected Expenditure: \$998,463

Actual Expenditure: \$962,357